TRT Injection Sites: Where To Inject Testosterone Safely

The injection site chosen for testosterone replacement therapy affects how the medication absorbs, how much discomfort occurs, and how stable hormone levels stay between doses. For men prescribed injectable testosterone cypionate or enanthate for diagnosed hypogonadism, the four most common TRT injection sites are the ventrogluteal (hip), vastus lateralis (outer thigh), deltoid (shoulder), and subcutaneous tissue (abdomen or thigh fat).

Each site carries different trade-offs. Intramuscular sites allow larger volumes and faster absorption. Subcutaneous sites use smaller needles and may produce steadier hormone levels. The right choice depends on dose volume, individual anatomy, comfort, and provider guidance based on lab results and clinical evaluation.

A 52-week registration study of subcutaneous testosterone enanthate found that 92.7% of participants reached a mean total testosterone of 300-1,100 ng/dL, with more than 95% reporting no injection-related pain (Kaminetsky et al., 2019). Injection tolerance directly affects long-term adherence, and adherence is one of the most important factors in maintaining a consistent therapeutic range.

What Are the Most Common TRT Injection Sites?

Injectable testosterone for hypogonadism is administered either intramuscularly (into a muscle) or subcutaneously (into fatty tissue beneath the skin). The AUA guideline on testosterone deficiency recommends that providers discuss injection route and site selection as part of treatment planning (Mulhall et al., 2018).

*Maximum volumes are based on general IM injection references. Most testosterone replacement doses fall within 0.5-1 mL per injection.

Dose volume is the first filter. Patients on higher-volume doses (1 mL or more) typically need a ventrogluteal or vastus lateralis site. Patients on lower-volume, more frequent dosing (0.3-0.5 mL) have all four sites available.

How Does the Ventrogluteal Site Work for Testosterone Injections?

The ventrogluteal site sits on the side of the hip, over the gluteus medius and gluteus minimus muscles. It's the intramuscular site most nursing references recommend because of its thick muscle mass and low proximity to major nerves and blood vessels.

The dorsogluteal site (upper outer buttock) was historically common but carries a higher risk of sciatic nerve injury. Most clinical training programs have moved away from it.

For self-injection, the patient places the heel of the opposite hand on the greater trochanter (the bony prominence at the hip) and spreads the index and middle fingers toward the iliac crest to form a V. The injection goes into the center of that V. This site accommodates volumes up to 3 mL and works well for standard weekly or biweekly dosing with testosterone cypionate or enanthate.

Is the Outer Thigh a Good Site for TRT Injections?

The vastus lateralis, located on the outer middle third of the thigh, is one of the most accessible intramuscular sites for self-administration. It sits in the patient's direct line of sight, requires no reaching behind the body, and accommodates the same volume range as the ventrogluteal site.

To locate it, the thigh is divided into three equal horizontal sections. The injection goes into the outer portion of the middle third. This site is widely used in testosterone replacement therapy but does carry a slightly higher risk of post-injection soreness, because the vastus lateralis is more involved in daily activities like walking and climbing stairs.

Rotating between the left and right thigh helps reduce local irritation over time.

When Is the Deltoid Used for Testosterone Injections?

The deltoid muscle in the upper arm is limited by its smaller size. Most clinical references restrict deltoid injections to volumes of 1 mL or less, making it suitable for smaller, more frequent doses. The injection goes into the thickest part of the deltoid, roughly two to three finger-widths below the acromion process (the bony point at the top of the shoulder).

The deltoid is easy to access for self-injection. Its vascularity may support relatively quick absorption, though comparative data across IM sites for testosterone esters is limited. It contains more nerve endings than larger muscle groups, and some patients report transient soreness. For patients on low-volume protocols (0.3-0.5 mL), alternating between the left and right deltoid combined with at least one additional site is a viable rotation strategy.

How Does Subcutaneous Testosterone Injection Compare to Intramuscular?

Subcutaneous injection delivers testosterone into the fatty tissue layer just beneath the skin. The abdomen (about 3-5 cm lateral to the navel) and the anterior thigh are the two most common subcutaneous sites.

Available data suggest this route may produce a slower release and smaller peak-to-trough fluctuations compared to intramuscular injection, though head-to-head comparison data remain limited. The Kaminetsky et al. (2019) study of weekly subcutaneous testosterone enanthate reported a mean trough concentration of 487.2 ng/dL at week 52, with no study drug-related serious adverse events (Kaminetsky et al., 2019).

A separate 26-week safety study of 133 men with testosterone deficiency confirmed a stable pharmacokinetic profile with subcutaneous dosing. Trough testosterone levels fell within 300-650 ng/dL in 82.4% of participants at week 12, and only 1 of 965 assessed injections produced mild pain (Gittelman et al., 2019). That tolerability data may help explain the increasing clinical interest in subcutaneous protocols for patients on lower-volume dosing.

Subcutaneous sites typically accept up to 0.5 mL per injection. Larger doses either need to be split across two sites or administered intramuscularly. Small nodules or mild irritation can occur at the injection site, particularly without rotation.

Why Does Injection Site Rotation Matter?

Repeated injection into the same tissue can lead to local inflammation, scarring, and over time, lipohypertrophy (fatty tissue buildup) or lipoatrophy (fatty tissue loss). Both conditions may change how testosterone absorbs from that area, which can contribute to inconsistent blood levels between injections.

For patients receiving weekly injections, a minimum of four distinct sites gives each location at least three weeks of recovery. A practical intramuscular rotation:

1. Right ventrogluteal

2. Left vastus lateralis

3. Left ventrogluteal

4. Right vastus lateralis

Patients using subcutaneous injections can alternate between the right and left abdomen and the right and left anterior thigh. Regardless of route, the injection spot within each site should shift slightly (about 2.5 cm) from the previous injection to avoid repeated trauma to the same tissue.

What Hygiene Practices Are Required for TRT Injections?

Injectable testosterone is a Schedule III controlled substance, and proper injection technique is part of safe use.

• Wash hands with soap and water before preparing the injection.

• Use a new, sterile needle and syringe every time. Never reuse or share needles.

• Clean the injection site with an alcohol swab and let it air dry before inserting the needle.

• Use a separate drawing needle (18G) and injecting needle (23-25G for IM, 25-30G for subcutaneous) to keep the injecting needle sharp.

• Dispose of all sharps in an FDA-cleared sharps container.

If redness, swelling, warmth, or drainage develops at an injection site, or if a fever occurs after injection, contact a licensed provider.

Testosterone therapy requires ongoing lab monitoring as directed by the prescribing provider. The Endocrine Society guideline recommends periodic blood work in the early months of therapy and at regular intervals thereafter (Bhasin et al., 2018). Routine monitoring may identify changes in red blood cell concentration or other markers that require dose adjustment (Mulhall et al., 2018).

How to Choose the Right TRT Injection Site

The right choice depends on prescribed dose volume, individual anatomy, comfort tolerance, and whether the patient self-injects or has assistance. For volumes above 1 mL per injection, the ventrogluteal or vastus lateralis sites are generally preferred. Patients on lower-volume, more frequent protocols (such as 0.3-0.5 mL twice weekly) can use any of the four sites, including subcutaneous.

The TRAVERSE trial, the largest cardiovascular safety trial of testosterone therapy (5,246 men), found that testosterone was noninferior to placebo for major adverse cardiac events. It also identified secondary signals including higher incidence of atrial fibrillation and pulmonary embolism in the testosterone group (Lincoff et al., 2023). These findings led the FDA to update testosterone labeling in February 2025, removing the prior cardiovascular boxed warning and adding a blood pressure warning.

Consistent dosing and monitoring are what keep patients in a safe therapeutic range. Inconsistent injection technique or inadequate rotation may affect how reliably the medication is absorbed. A licensed provider can recommend the right site, needle gauge, and rotation schedule based on the patient's prescribed formulation, dose, and individual anatomy.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

What are the best TRT injection sites for self-administration? 

The vastus lateralis (outer thigh) and deltoid (shoulder) are the most accessible for self-injection because they are in the patient's direct line of sight and don't require reaching behind the body. The ventrogluteal site is also an option with practice. Site selection should be based on dose volume, individual anatomy, and provider recommendation.

Does subcutaneous testosterone injection work as well as intramuscular? 

Clinical data suggests comparable outcomes. A 52-week study found that 92.7% of men on weekly subcutaneous testosterone enanthate reached a mean total testosterone of 300-1,100 ng/dL (Kaminetsky et al., 2019). Subcutaneous injection may produce steadier hormone levels with smaller peak-to-trough variation, though individual responses vary.

How often should TRT injection sites be rotated? 

Every injection should use a different site than the previous one. A rotation of at least four distinct sites gives each location three or more weeks of recovery between injections. Within each site, shifting the exact injection spot by about 2.5 cm (1 inch) prevents repeated trauma to the same tissue.

What needle size is used for testosterone injections? 

Intramuscular injections typically use a 22-25 gauge needle, 1 to 1.5 inches in length. Subcutaneous injections use a smaller 25-30 gauge needle, 0.5 to 0.625 inches long. A separate 18G drawing needle is recommended for loading the syringe, then swapping to the injection needle to keep it sharp.

What happens if the same TRT injection site is used repeatedly? 

Repeated injection into the same tissue can lead to local inflammation, scarring, lipohypertrophy (fatty tissue buildup), or lipoatrophy (fatty tissue loss). These changes may affect how testosterone absorbs from that area, which can contribute to inconsistent hormone levels between doses.

What monitoring is required during testosterone replacement therapy? 

Clinical guidelines recommend periodic blood work in the early months of therapy and at regular intervals thereafter, with specific timing determined by the prescribing provider (Bhasin et al., 2018). Routine monitoring may identify changes in red blood cell concentration or other markers that require dose adjustment (Mulhall et al., 2018).

Is testosterone a controlled substance? 

Testosterone is classified as a Schedule III controlled substance under the Anabolic Steroid Control Act. Prescriptions require clinical evaluation and lab confirmation of testosterone deficiency, typically defined as a total testosterone consistently below 300 ng/dL on two separate early-morning blood draws plus the presence of symptoms.

References

• J Urol. 2018;200:423-432

• J Clin Endocrinol Metab. 2018;103(5):1715-1744

• N Engl J Med. 2023;389:107-117 

• J Urol. 2019;201(3):587-594

• J Sex Med. 2019;16(11):1741-1748

• FDA Drug Safety Communication (Feb 2025)